We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Arca is helping to build the market for property market risk transfer by dealing in derivatives for domestic and commercial properties. Nick Ruddell has held senior roles for the last 30 years with banks and big interdealer brokers.
days to go: Expired investment: £676,500
Howsy is a property management app that aims to make renting a satisfactory experience for landlords and tenants. The company claims to have created a digital ecosystem that removes traditional agents, bringing down the cost of managing a property by an estimated 75% and delivering satisfactory customer service. Howsy has 7,000 properties on its platform mixed between recurring revenue and one-off customers. It has also acquired two of the largest online agents in the UK, Upad and Happy Tenant Company, in December 2019 and September 2020, respectively. Howsy asserts that it has achieved a 130% year-on-year revenue growth despite the COVID-19 pandemic and has featured in press entities like Forbes, The Guardian, TechCityNews, and Startups.co.uk, amongst others. It will use the investment for working capital allocation across marketing, general/admin, and technology. It will also use the funds to provide a stable runway to its Series A funding round, which it hopes to complete by January 2022.
days to go: Expired investment: £824,280
BiVictriX Therapeutics is a pharmaceutical company that are developing ADC's (Antibody Drug Conjugates) in the field of Oncology. They have invented a strategy that improves ADC selectivity towards cancer cells.
days to go: Expired investment: £451,506
Please watch the video for more information
days to go: Expired investment: £1,579,480
A technological healthcare service allowing patients to discuss any concerns with a GP, clinician or specialists via video consultations, home visits, or appointments at the clinic. DocNoc launched less than 12 months ago and has over 160 NHS and private sector doctors and clinics registered on the service. The company's business model is easily flexible and aim to launch DocNoc internationally.
days to go: Expired investment: £269,710
Advanced Blast & Ballistic Systems (ABBS) is a company that has developed globally patented systems to counteract the forces an armoured vehicle sustains when a mine or Improvised Explosive Device (IED) explodes under it. As per reports, mines and IEDs accounted for over 80% of UK and US army casualties in Iraq & Afghanistan. ABBS believes that its products can keep occupants inside a vehicle completely safe from the aforementioned explosive devices. The armoured vehicle protection market has a value of about $20 billion wherein ABBS aims to be a major contender. The company has received £2 million-plus revenues till date from Research and Development (R&D) grants in the UK, as well as, sold its products to the US Army and Israel with profits worth £145,000 in 2018 and £560,000 in 2019 respectively. It will use the investment to bring its products to more markets globally.

Pitch Rated

78%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £445,814
Ultramed are a health tech company, placing patient experience and innovation at the forefront. They operate a suite of cloud based pre operative products by combining clinical NHS operative experience. The aim is to reduce costs increase health care resources.
days to go: Expired investment: £317,540
Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £270,543
planarTECH is an engineering company founded in 2014 as a provider of process equipment for the growth and characterisation of graphene and other emerging 2D materials. Its core product line is the planarGROW Chemical Vapor (CVD) system. The company has the ability to deliver scalable production systems that allow lower-cost production of graphene in comparison to other options currently available in the market. Moreover, from 2014 to 2019, the company’s cumulative revenues exceeded £5 million. The company's products have been installed and used by faculties and students at prestigious universities like Stanford University (USA), IIT- Bombay (India), Deakin University (Australia), and many others. From the investment, the company will utilise 45% as working capital, 30% in Capital Expenditures (CAPEX), 15% in R&D and 10% in hiring additional staff.

Pitch Rated

47%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £425,061
I Am The Agent are a data-driven property hub charging property owners fixed-price online sales and rental packages. Since launching in 2011, the company has served over 150,000 clients and has achieved nearly £700k revenue. 
days to go: Expired investment: £206,310
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph